Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Novo Nordisk, PepsiCo, Cencora, and Lemonade. CBP seizes rocket launcher at Arizona port 5 Expenses Parents Should Stop ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...